Sparsentan Promising for Focal Segmental Glomerulosclerosis

Focal segmental glomerulosclerosis is on the rise and thus far without an approved therapy. Watch Howard Trachtman, MD, FASN, professor at New York University Langone Medical Center, discuss findings of the DUET study at Kidney Week 2016.

[@maahii8219]

When this product will be available in market?

[@russelmiller7311]

Sparsentan, also known as RE-021, BMS346567, is a dual antagonist of both angiotensin II and endothelin A receptor antagonist.-reference from www.bocsci.com/sparsentan-cas-254740-64-2-item-475592.html

[@bharathimurthy1572]

when this product is available in the market

[@GautamSingh-ix9si]

Sir what is FSGS can u explain becoz I had a biopsy, it has under in FSGS Progress and 30% kidney damage, then there is no treatment. 😭
I hope you can advise me something and Which medicine good for FSGS patients ???

[@garimajoshi1622]

Availability in the market??

[@meunpredictableme]

When it will availble in market